Article Text

Download PDFPDF

812 Reprograming of tumor-associated myeloid cells by TLR9-targeted STAT3 antisense oligonucleotides sensitizes malignant glioma to PD1-specific immunotherapy
  1. Chia-Yang Hung1,
  2. Elaine Kang1,
  3. Karol Jacek2,
  4. Chunsong Yu1,
  5. Xiaowei Zhang1,
  6. Susanta Hui1,
  7. Behnam Badie1,
  8. Bozena Kaminska2,
  9. Amy Heimberger3 and
  10. Marcin Kortylewski1
  1. 1Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
  2. 2Nencki Institute of Experimental Biology, Warsaw, Poland
  3. 3Northwestern University, Chicago, IL, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Malignant gliomas (MG) are rapidly fatal despite multimodal treatments including radiation therapy, used to treat nearly all MG patients, or even the emerging cellular immunotherapies. Therapeutic resistance in glioma is at least partly related to tolerogenic STAT3 activity in both glioma cancer stem cells (GCSs) and in the tumor-associated myeloid immune cells, such as macrophages and microglia, which dominate MG microenvironment. We previously demonstrated that STAT3 activity in GSCs and tumor-associated myeloid cells can be targeted using Toll-like Receptor-9 (TLR9)-targeted oligonucleotide therapeutics such as siRNA or antisense oligonucleotides (ASO).1–3

Methods Here, we describe development of a new TLR9-targeted and double-stranded STAT3 antisense oligonucleotide (CpG-STAT3dsASO) with optimized efficacy and tolerability for glioma immunotherapy.

Results Compared to our benchmark ASO oligonucleotides, the locked nucleic acid (LNA)-modified CpG-STAT3dsASO showed enhanced STAT3 knockdown in human and in mouse glioma cells and also in TLR9+ immune cells, such as macrophages and microglia. When tested against orthotopic model of human U251 glioma, intracranial injections of CpG-STAT3dsASO (1 mg/kg/q2w) inhibited tumor growth and significantly extended survival of immunodeficient NSG mice compared to benchmark oligonucleotide. Next, we tested the efficacy of CpG-STAT3dsASO against syngeneic GL261 or QPP8 glioma in immunocompetent mice.4 Our initial results demonstrated that CpG-STAT3dsASO was more effective and significantly better tolerated than single-stranded CpG-STAT3ASO when injected intracranially. All tested CpG-STAT3ASO variants induced activation of intratumoral DCs, macrophages and microglia, while reducing numbers of tumor-associated macrophages (TAMs), resting microglia and regulatory T cells as assessed using flow cytometry. However, the intratumoral recruitment of effector CD8 T cells was limited. To improve CD8 T cell activation, we next combined intracranial CpG-STAT3dsASO administration at low 0.25 mg/kg dosing with systemic PD1 blockade. The anti-PD1/CpG-STAT3dsASO combination triggered complete rejection of both orthotopic GL261 and the PD1-refractory QPP8 tumors in the majority of treated mice, while neither treatment was curative alone. Importantly, Our single-cell transcriptomic analysis and spatial profiling of the brain sections from all treatment groups confirmed the complementary effect of CpG-STAT3dsASO and PD1 blockade on the glioma microenvironment. CpG-STAT3dsASO reprogrammed glioma-associated myeloid cells into antigen-presenting cells and phagocytes, expanded Th1 CD4 lymphocytes while reducing Treg percentages. These conditions unlocked the potential of PD1 blockade to recruit effector CD8 T cells into glioma without indication of lymphocyte exhaustion.

Conclusions Our results underscore the potential of using myeloid cell-targeted CpG-STAT3dsASO to overcome glioma immune evasion and thereby to sensitize tumors to PD1 immune checkpoint blockade and potentially other T-cell based cancer immunotherapies.

Acknowledgements This work was supported by the NCI/NIH award R01CA215183 (to M.K.). The content is the responsibility of the authors and does not necessarily represent the official views of the NIH.


  1. Herrmann A, Cherryholmes G, Schroeder A, Phallen J, Alizadeh D, Xin H, Wang T, Lee H, Lahtz C, Swiderski P, Armstrong B, Kowolik C, Gallia GL, Lim M, Brown C, Badie B, Forman S, Kortylewski M, Jove R, Yu H. TLR9 is critical for glioma stem cell maintenance and targeting. Cancer Res. 2014;18:5218–5228.

  2. Moreira D, Adamus T, Zhao X, Su Y-L, Zhang Z, White SV, Swiderski P, Lu X, DePinho RA, Pal SK, Kortylewski M. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin Cancer Res. 2018;23:5948–5962.

  3. Adamus T, Hung C-Y, Yu C, Kang E, Hammad M, Flores L, Nechaev S, Zhang Q, Gonzaga JM, Muthaiyah K, Swiderski P, Aboody KS, Kortylewski M. Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells. Mol Ther Nucleic Acids. 2022;27:611–620.

  4. Chen C-H, Chin RL, Hartley GP, Lea ST, Engel BJ, Hsieh C-E, Prasad R, Roszik J, Shingu T, Lizee GA, Heimberger AB, Millward SW, Hu J, Hong DS, Curran MA. Novel murine glioblastoma models that reflect the immunotherapy resistance profile of human disease. Neuro Oncol. 2023; e-pub.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.